Thiogenesis Therapeutics Corp (TTI) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tti-0102: Cysteamine-Pantetheine Disulfide, D-Mannitol | Leigh Syndrome | Phase II | Not Yet Recruiting | A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) | May 06, 2025 | ― |
| Tti-0102 | Melas Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis And Stroke-Like Episodes (Melas) | Phase II | Recruiting | A Study to Assess TTI-0102 vs Placebo in MELAS Patients | Sep 29, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tti-0102: Cysteamine-Pantetheine Disulfide, D-Mannitol | Phase II | Leigh Syndrome | Not Yet Recruiting | A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) | May 06, 2025 | ― |
| Tti-0102 | Phase II | Melas Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis And Stroke-Like Episodes (Melas) | Recruiting | A Study to Assess TTI-0102 vs Placebo in MELAS Patients | Sep 29, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Thiogenesis Therapeutics Corp (TSE:TTI) have in its pipeline
Thiogenesis Therapeutics Corp TSE:TTI is currently developing the following drugs: Tti-0102: Cysteamine-Pantetheine Disulfide, D-Mannitol, Tti-0102. These drug candidates are in various stages of clinical development as the company works toward FDA approval.